Predictors of fatal and nonfatal cardiovascular events in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia: An analysis of the Trial to Reduce cardiovascular Events with Aranesp (darbepoetin-alfa) Therapy (TREAT)
- 31 October 2011
- journal article
- research article
- Published by Elsevier BV in American Heart Journal
- Vol. 162 (4), 748-755.e3
- https://doi.org/10.1016/j.ahj.2011.07.016
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Extensions of net reclassification improvement calculations to measure usefulness of new biomarkersStatistics in Medicine, 2010
- Awareness and behaviour of European physicians in relation to microalbuminuria and organ damage: an ESH-endorsed surveyJournal of Hypertension, 2010
- Recommendations for the use of cardiac troponin measurement in acute cardiac careEuropean Heart Journal, 2010
- Anaemia, independent of chronic kidney disease, predicts all-cause and cardiovascular mortality in type 2 diabetic patientsAtherosclerosis, 2010
- Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysisThe Lancet, 2010
- A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney DiseaseNew England Journal of Medicine, 2009
- Albuminuria and Kidney Function Independently Predict Cardiovascular and Renal Outcomes in DiabetesJournal of the American Society of Nephrology, 2009
- Cardiovascular risk factors in patients with chronic kidney diseaseNature Reviews Cardiology, 2009
- Anemia as a Risk Factor for Cardiovascular Disease and All-Cause Mortality in DiabetesJournal of the American Society of Nephrology, 2005
- Predictors of cardiovascular events in patients with type 2 diabetic nephropathy and hypertension: A case for albuminuriaKidney International, 2004